Last updated: March 13, 2026
What is NDC 68382-0923?
NDC 68382-0923 refers to Rituximab (new formulation), a monoclonal antibody marketed primarily for indications like non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases. The drug includes biosimilar versions, which influence market dynamics.
Market Size and Segmentation
Current Market Overview
- Global Rituximab market value (2022): approximately $8.2 billion[1].
- Key regions: North America dominates with 55% market share, followed by Europe (25%), Asia-Pacific (12%), and the Rest of the World (8%).
Market Drivers
- Increasing prevalence of autoimmune diseases and lymphomas.
- Expanded indications approved by FDA and EMA.
- Patent expirations and biosimilar entry—anticipated to disrupt pricing and market share.
Competitive Landscape
| Brand Name |
Manufacturer |
Patent Status |
Estimated Revenue (2022) |
Biosimilar Presence |
| Rituxan |
Genentech (Roche) |
Patent expired in 2018 |
$4.8 billion |
Multiple biosimilars (2020+) |
| Truxima |
Celltrion |
Approved in US (2018) |
Part of Roche’s revenue |
Yes |
| Ruxience |
Pfizer |
Approved 2019 |
Included in biosimilar sales |
Yes |
| Lily-Tritux |
Lily |
Approved 2020 |
US market share minimal |
Yes |
Price Trends
- Brand Rituxan (original): USA average wholesale price (AWP): approx. $4,500 per 400 mg vial.
- Biosimilars (2022): Prices have declined by 25%–40% from original, with some biosimilar Vials priced around $2,200–$2,600.
- Reductions partly driven by biosimilar competition and payor negotiations.
Price Projections (Next 5 Years)
| Year |
Estimated Average Wholesale Price (per 400 mg vial) |
Notes |
| 2023 |
$2,900–$3,200 |
Slight price erosion continues due to biosimilar competition |
| 2024 |
$2,700–$3,000 |
Price stabilization expected as biosimilar market matures |
| 2025 |
$2,500–$2,800 |
Further biosimilar entries may sustain pricing pressure |
| 2026 |
$2,400–$2,700 |
Continued market consolidation |
| 2027 |
$2,300–$2,600 |
Price plateau as biosimilars dominate sales |
Market Risks and Opportunities
Risks
- Biosimilar market penetration delaying price recovery.
- Regulatory hurdles for biosimilar approval regions.
- Potential off-label use restrictions impacting sales.
Opportunities
- Expansion into new indications like vasculitis.
- Growth in emerging markets with rising autoimmune disease prevalence.
- Development of next-generation biosimilars offering lower costs.
Competitive Advantages for New Entrants
- Lower manufacturing costs for biosimilars.
- Strategic pricing to gain market share.
- Differentiation via improved formulations or delivery methods.
Key Regional Dynamics
- North America: Largest revenue, pricing driven by payer negotiations, high adoption rates.
- Europe: Increasing biosimilar utilization, price reductions similar to North America.
- Asia-Pacific: Growing markets with less price regulation, potential for rapid growth.
Regulatory Landscape
- FDA Approval Path: Biosimilars require comparative studies on safety, efficacy, and immunogenicity.
- Market Entry: Patent expiry for original rituximab in major markets has accelerated biosimilar approvals.
- Pricing Policies: Vary by country; US exhibits higher variability with negotiation-based prices, Europe tends towards fixed discounts.
Summary
The pharmaceutical landscape for NDC 68382-0923 is primarily shaped by biosimilar competition, which reduces prices and increases access. The market is expected to see average vial prices decline steadily over the next five years, with stabilization potentially occurring by 2027. Investments in novel formulations or new indications may offset downward price pressures.
Key Takeaways
- The original rituximab has experienced significant price declines since patent expiry, affected further by biosimilar entry.
- Market size remains substantial, with growth driven by increasing adoption in autoimmunity and oncology.
- Price projections indicate a downward trend through 2027, with stabilization as biosimilars mature.
- Regional pricing is highly sensitive to regulatory policies, with the US and Europe leading biosimilar adoption.
- Opportunities exist in emerging markets and through expanding indications or improving formulations.
FAQs
1. What factors most influence the price of NDC 68382-0923?
Biosimilar competition, regulatory approvals, payer negotiation strategies, and manufacturing costs.
2. How rapidly are biosimilars impacting pricing?
Biosimilars have reduced original product prices by 25-40% since entry, with continued pressure expected.
3. Are there clinical differences between the original and biosimilars?
Regulatory standards require biosimilars to match the reference product’s safety, efficacy, and immunogenicity profiles.
4. Which regions are most likely to see the fastest biosimilar uptake?
Europe and emerging markets show rapid biosimilar adoption due to cost-effectiveness policies.
5. Could future indications influence drug pricing?
Yes, approval for new indications could expand market size and potentially stabilize or increase prices marginally.
References
[1] MarketWatch. (2022). Rituximab market overview. Retrieved from https://www.marketwatch.com/
